KR930001910A - 혈압강하 배합물 - Google Patents
혈압강하 배합물 Download PDFInfo
- Publication number
- KR930001910A KR930001910A KR1019920012932A KR920012932A KR930001910A KR 930001910 A KR930001910 A KR 930001910A KR 1019920012932 A KR1019920012932 A KR 1019920012932A KR 920012932 A KR920012932 A KR 920012932A KR 930001910 A KR930001910 A KR 930001910A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- pyridazodizepine
- alkyl
- tetrahydronaphthalene derivative
- combination
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 4
- 238000009472 formulation Methods 0.000 title claims description 3
- 208000001953 Hypotension Diseases 0.000 title 1
- 208000021822 hypotensive Diseases 0.000 title 1
- 230000001077 hypotensive effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실라자프릴 및 화합물 A의 단독 투여 효과 및 이들 2가지 물질의 동시 투여 효과를 예시하며,
제2도는 배합물의 상승 효과를 보여주고,
제3도는 실라자프릴, 화합물 A및 이들 성분의 배합물이 중막 면적에 미치는 효과를 비교한 것이다,
Claims (5)
- 유리 염기, 수화물 또는 약제학적으로 유용한 염의 형태의 일반식(I)의 테트라하이드로나프탈렌 유도체 및 일반식(II)의 피리다조디아제핀을 함유하는 약제학적 배합물.상기식에서, R1은 할로겐이고, R2는 저급-알콕시-저급-알킬카보닐옥시이며, R4는 알킬 잔기중의 C1-6-아르알킬 또는 할로겐, C1-6-알콕시 또는 페닐에 의해 임의로 일치환된 아릴 잔기로서의페닐이고, R5및 R6는 각각 독립적으로 수소 또는 C1-6알킬이며, R7및 R8은 각각 독립적으로 수소이거나 함께 옥소 그룹을 형성하고, X는 C2-8알킬렌이며, A는 C1-2알킬에 의해 질소 원자에서 임의로 치환된 벤즈 이미다졸릴이다.
- 제1항에 있어서, 피리다조디아제핀에 대한 테트라하이드로나프탈렌 유도체의 중량비가 20 : 1 내지 2 : 1인 배합물.
- 제1항에 있어서, 일반식(I)의 테트라하이드로나프탈렌 유도체로서 [1S,2S]-2-[2-[2-[[3-(2-벤즈이미다졸릴)프로필]메틸아미노]에틸]-6-플루오로-1,2,3,4-테트라하이드로-1-이소프로필-2-나프틸메톡시아세테이트 디하이드로클로라이드를 함유하는 배합물.
- 제1항에 있어서, 일반식(II)의 피리다조디아제핀으로서 9(S)-[1(S)-에톡시카보닐-3-페닐프로필아미노]옥타하이드로-10-옥소-6H-피리다조[1,2-a][1,2)디아제핀-1(S)-카복실산을 함유하는 배합물.
- 제1항 내지 제4항 중의 어느 한 항에 있어서, 순환계 질환, 특히 고혈압 및 이에 기인하는 질환의 억제 또는 예방에 동시에, 따로 또는 계획된 단계에 따라 사용하기 위한 배합물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH219191 | 1991-07-23 | ||
CH02-191/91-2 | 1991-07-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR930001910A true KR930001910A (ko) | 1993-02-22 |
KR100260479B1 KR100260479B1 (ko) | 2000-07-01 |
Family
ID=4228024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920012932A KR100260479B1 (ko) | 1991-07-23 | 1992-07-21 | 혈압강하용 복합제제 |
Country Status (31)
Country | Link |
---|---|
US (1) | US5620975A (ko) |
EP (1) | EP0524512B1 (ko) |
JP (1) | JPH0680009B2 (ko) |
KR (1) | KR100260479B1 (ko) |
CN (1) | CN1040505C (ko) |
AT (1) | ATE260661T1 (ko) |
AU (1) | AU656207B2 (ko) |
BG (1) | BG60949B1 (ko) |
BR (1) | BR9202830A (ko) |
CA (1) | CA2074039C (ko) |
CZ (1) | CZ281691B6 (ko) |
DE (1) | DE59209993D1 (ko) |
DK (1) | DK0524512T3 (ko) |
ES (1) | ES2215160T3 (ko) |
HR (1) | HRP930953B1 (ko) |
HU (1) | HU214029B (ko) |
IE (1) | IE922378A1 (ko) |
IL (1) | IL102541A (ko) |
IS (1) | IS3887A (ko) |
MX (1) | MX9204212A (ko) |
MY (1) | MY118064A (ko) |
NO (1) | NO301047B1 (ko) |
NZ (1) | NZ243577A (ko) |
PT (1) | PT524512E (ko) |
RO (1) | RO110905B (ko) |
RU (1) | RU2084225C1 (ko) |
SK (1) | SK278918B6 (ko) |
TW (1) | TW216770B (ko) |
UY (1) | UY23449A1 (ko) |
YU (2) | YU49198B (ko) |
ZA (1) | ZA925322B (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59409631D1 (de) * | 1993-07-15 | 2001-02-15 | Hoffmann La Roche | Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält |
IL131816A (en) | 1997-04-04 | 2003-06-24 | Exxon Res & Engineering Compan | Composite structures having high containment strength |
US6608097B2 (en) | 2001-10-10 | 2003-08-19 | Aryx Therapeutics | Materials and methods for the treatment of hypertension and angina |
US7687086B1 (en) | 2003-02-28 | 2010-03-30 | University Of Portland | Method for obtaining taxanes |
EP2537534B1 (en) | 2011-06-22 | 2014-12-17 | Hexal AG | Esters of (1S,9S)-9-[[(1S)-1-carboxy-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid and their therapeutic use. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2128984B (en) * | 1982-05-12 | 1985-05-22 | Hoffmann La Roche | Diaza-bicyclic compounds |
DE3542794A1 (de) * | 1985-12-04 | 1987-06-11 | Bayer Ag | Antihypertensives kombinationspraeparat |
CA1319144C (en) * | 1986-11-14 | 1993-06-15 | Quirico Branca | Tetrahydronaphthalene derivatives |
FR2607004B1 (fr) * | 1986-11-20 | 1990-06-01 | Synthelabo | Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine |
US5110813A (en) * | 1987-09-15 | 1992-05-05 | Alcoholism And Drug Addiction Research Foundation | Reduction of voluntary alcohol consumption by treatment with angiotensin converting enzyme inhibitors |
US4871731A (en) * | 1987-10-07 | 1989-10-03 | Marion Laboratories, Inc. | Captopril and diltiazem composition and the like |
KR940005408B1 (ko) * | 1990-12-03 | 1994-06-18 | 만도기계 주식회사 | 파워 윈도우 모우터 회전자의 선단부 흔들림 측정장치 |
-
1992
- 1992-07-04 TW TW081105301A patent/TW216770B/zh active
- 1992-07-11 EP EP92111847A patent/EP0524512B1/de not_active Expired - Lifetime
- 1992-07-11 DK DK92111847T patent/DK0524512T3/da active
- 1992-07-11 AT AT92111847T patent/ATE260661T1/de not_active IP Right Cessation
- 1992-07-11 ES ES92111847T patent/ES2215160T3/es not_active Expired - Lifetime
- 1992-07-11 PT PT92111847T patent/PT524512E/pt unknown
- 1992-07-11 DE DE59209993T patent/DE59209993D1/de not_active Expired - Fee Related
- 1992-07-16 ZA ZA925322A patent/ZA925322B/xx unknown
- 1992-07-16 CA CA002074039A patent/CA2074039C/en not_active Expired - Fee Related
- 1992-07-16 NZ NZ243577A patent/NZ243577A/en unknown
- 1992-07-17 IL IL10254192A patent/IL102541A/en not_active IP Right Cessation
- 1992-07-17 MX MX9204212A patent/MX9204212A/es active IP Right Grant
- 1992-07-20 RU SU925052378A patent/RU2084225C1/ru not_active IP Right Cessation
- 1992-07-20 AU AU20416/92A patent/AU656207B2/en not_active Ceased
- 1992-07-20 HU HU9202367A patent/HU214029B/hu not_active IP Right Cessation
- 1992-07-21 RO RO92-0990A patent/RO110905B/ro unknown
- 1992-07-21 BG BG96664A patent/BG60949B1/bg unknown
- 1992-07-21 MY MYPI92001289A patent/MY118064A/en unknown
- 1992-07-21 SK SK2270-92A patent/SK278918B6/sk unknown
- 1992-07-21 KR KR1019920012932A patent/KR100260479B1/ko not_active IP Right Cessation
- 1992-07-21 CZ CS922270A patent/CZ281691B6/cs not_active IP Right Cessation
- 1992-07-22 CN CN92108668A patent/CN1040505C/zh not_active Expired - Fee Related
- 1992-07-22 IE IE237892A patent/IE922378A1/en not_active Application Discontinuation
- 1992-07-22 NO NO922903A patent/NO301047B1/no not_active IP Right Cessation
- 1992-07-22 UY UY23449A patent/UY23449A1/es not_active IP Right Cessation
- 1992-07-23 YU YU72392A patent/YU49198B/sh unknown
- 1992-07-23 JP JP4216629A patent/JPH0680009B2/ja not_active Expired - Fee Related
- 1992-07-23 IS IS3887A patent/IS3887A/is unknown
- 1992-07-23 YU YU72392A patent/YU72392A/sh unknown
- 1992-07-23 BR BR929202830A patent/BR9202830A/pt not_active Application Discontinuation
-
1993
- 1993-06-07 HR HR930953A patent/HRP930953B1/xx not_active IP Right Cessation
-
1994
- 1994-11-02 US US08/333,171 patent/US5620975A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR890701562A (ko) | 면역조절 아자스 피란류 | |
KR880013888A (ko) | 신규 디티오아세탈 화합물, 그의 제조방법 및 이 화합물로 되는 제약 조성물 | |
DK490288A (da) | Substituerede thiazolidindionderivater | |
KR930703243A (ko) | 방향족 설폰아미드계 하이드록삼산 유도체 | |
KR900018073A (ko) | 피페라진 화합물 | |
KR900003151A (ko) | 화합물 | |
KR890012970A (ko) | 테트라히드로 이소퀴놀린 유도체 | |
KR900003163A (ko) | 시클로헥산 유도체 | |
KR970707108A (ko) | 항염증제로 유용한, 복소환부를 갖는 디-t-부틸페놀 화합물(DI-TERT-BUTYLPHENOL COMPOUNDS WITH HETEROCYCLIC MOIETY, USEFUL AS ANTI-INFLAMMATORY AGENTS) | |
ATE156119T1 (de) | 2-formylpyridin-thiosemicarbazonderivate, ihre herstellung und ihre verwendung als antitumor mittel | |
KR930001910A (ko) | 혈압강하 배합물 | |
KR920016448A (ko) | 피페리딘 유도체 | |
KR920019350A (ko) | 자기면역질환요법을 위한 약제조성물 | |
KR960034200A (ko) | 항편두통성 인돌릴알킬-피리딘일 및 피리미딘일피페라진의 1,2,5-티아디아졸 유도체 | |
ATE74924T1 (de) | N-(vinblastinoyl-23)-derivate von 1aminomethylposphons|ure, verfahren zu ihrer herstellung und sie enthaltende arzneimittel. | |
KR930021638A (ko) | 이미다조피리딘 | |
KR900012925A (ko) | 인돌 유도체 | |
ATE170851T1 (de) | Guanidinothiazolederivate und ihre anwendung als h2-rezeptor-antagonisten | |
KR890008121A (ko) | 로다닌 유도체 및 약제학적 조성물 | |
ATE1598T1 (de) | 5(10- 9)abeo-ergolin-derivate, ihre herstellung und sie enthaltende therapeutische zusammensetzungen. | |
KR950703956A (ko) | 순환 장애 개선제[circulatory disturbance ameliorant] | |
BE1002181A3 (fr) | 3-(2-haloalkyl)-1,4-oxathiines et 2-(2-haloalkyl)-1,4-dithiines, de meme que le traitement de la leucemie et des tumeurs avec ces substances. | |
OA09416A (fr) | Nouveaux dérivés triéniques de structure chroménique, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. | |
DK378087D0 (da) | Tetracycliske indolderivater | |
KR910007878A (ko) | 디히드로피리딘 유도체 및 의약 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20040331 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |